header logo image


Page 1,527«..1020..1,5261,5271,5281,529..1,5401,550..»

In Rare Negative Vote, CIRM Directors Nix $6.3 Million Grant Application

January 22nd, 2012 4:55 pm


Directors of the California stem cell agency today rejected a $6.3 million grant to recruit an unidentified researcher to the Buck Institute after some of CIRM's grant reviewers raised questions about his/her research, achievements and experience.

The CIRM governing board voted 3-16 with two abstentions on the grant, which scored 76 out of 100 during a closed-door session of reviewers earlier this month. Directors were told that the grants review group voted 11-6 to approve the application.

The CIRM board almost never rejects a recommendation from grant reviewers.

During the board's discussions, several directors raised questions about whether CIRM would be paying -- with the grant -- for research that did not fit within its objectives. Others said the intent of the agency's recruitment grant program was to attract the best scientists to California.

The research proposal was the subject of an unusual, dissenting minority report by reviewers. The CIRM staff-prepared review summary said,

"A motion to recommend the application for funding carried with a majority vote. Because the motion was opposed by more than 35% of members, opponents have exercised their right to have that position reported to the ICOC(the CIRM governing board). The GWG(grant review group) members raised three main opposing points. First, some GWG members were not convinced that the research program proposed by the candidate, despite its scientific merits in a simple model organism (the fruitfly Drosophila), would be translated effectively to mammalian models and human studies. Thus, they questioned whether the work would have significant impact on CIRM's mission of advancing stem cell research toward therapies. Second, some GWG members felt that the candidate's research vision did not extend far beyond significant discoveries to which the candidate has already contributed, and was, therefore, solid and safe but not venturesome or compelling. Third, although the candidate is clearly a rising star, some GWG members were concerned that the candidate's achievements and experience were not yet sufficiently mature for the leadership position expected under this award."

However, the review summary also said,

"The goal of the proposed research is to expand the study of molecular pathways mediating stem cell aging and to extend these investigations into mammalian cells....The proposed studies will investigate the regulation of stem cell activity and aging in response to nutritional conditions and environmental stress. These efforts could yield new insights into a range of chronic diseases and lead to therapeutic approaches to maintain or restore adult stem cell function in humans. "

"The candidate’s emerging leadership and recognition by the field has been reflected in numerous invitations to speak at major meetings and to contribute reviews and commentaries to leading journals. The PI (applicant) was lauded in outstanding letters from leaders in the field of stem cell aging research. They described the candidate as a highly energetic, innovative, and focused scientist who is recognized internationally as a critical thought leader making fundamental contributions to the understanding of aging mechanisms."

Normally the names of institutions connected to grant applications are not disclosed prior to board approval. However, the name of the Buck Institute was mentioned during the discussion about the application. Votes by the grants review group are also not normally disclosed during board discussions.

The award would have been the fourth in CIRM's $44 million programt to help recruit stem cell researchers to California.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Read More...

Two Potential Buyers Eyeing Geron’s hESC Business

January 22nd, 2012 4:55 pm


Geron has two interested potential buyers for its human embryonic stem cell business, the president of the California stem cell agency said today.

Alan Trounson told CIRM directors that at one point four parties had expressed interest  but two have backed out. He did not disclose the names of any of the parties.

Last fall, Geron announced it was giving up its hESC work because of financial concerns about what once was the first clinical trial of a human embryonic stem therapy. Last summer CIRM loaned Geron $25 million for the trial, which has been repaid with interest.  Following Geron's announcement, Trounson said he was working to help find a buyer for Geron's hESC business.

However, today he said he was "suddenly distanced" from the process a few days ago. CIRM director Sherry Lansing, who once headed a Hollywood film studio, asked Trounson whether there was anything that directors could do to help find a buyer for Geron's hESC business. She asked about the amount of money needed by Geron and whether patient advocates could help generate other momentum.

Trounson suggested that the discussion should  be continued privately. He did say that CIRM has prepared a document that outlines what would  be necessary for the agency to resume funding of the hESC trial.

Trounson told directors that Geron's departure from hESC research has had "a very strong negative influence internationally."

Geron, which is based in Menlo Park in California, said last week it has hired Stifel Nicolaus & Co. to help sell the hESC business. . 

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Read More...

California Stem Cell Agency Slated for More Bond Funding This Spring

January 22nd, 2012 4:55 pm


The California stem cell agency is slated to secure additional bond funding this spring when the financially troubled Golden State initiates a new round of borrowing.

CIRM Chairman Jonathan Thomas told directors today that the $3 billion agency will be involved  in the upcoming round. He did not specify the amount that CIRM would receive or the timing of the bond issue.

The agency's only significant funding comes from state bonds, whose funds flow directly to CIRM. The governor and legislature cannot touch the CIRM funds under the terms of the ballot measure that created the research effort in 2004.

Last year at this time, the state suspended bond sales. At the time, CIRM had sufficient funds to meet its commitments until about June of this year. Late last year, Thomas worked out a temporary funding arrangement with the governor's financial aides to cover any possible shortfall.

Thomas made the announcement at the beginning of today's CIRM board meeting in San Diego.

Currently CIRM President Alan Trounson is reviewing new stem cell research that has been published recently.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Read More...

Stem Cell Agency Shying Away From Another Multibillion-dollar Bond Proposal

January 22nd, 2012 4:55 pm


The $3 billion California stem cell agency, which is expected to run out of cash in five years, is backing away from an attempt to win voter approval of another multibillion dollar bond measure to finance its research efforts.

The agency disclosed its new position in a document posted in connection with the meeting tomorrow of its governing board in San Diego. CIRM said,

"Although additional funding could be a possibility in the future, it would be premature even to consider another bond measure at this time. Instead, CIRM should focus its efforts on creating a platform that enables others to carry on CIRM’s work."

The statement is a sharp departure from previous discussion of mounting a ballot campaign for a $4 billion to $5 billion bond measure on behalf of CIRM.

The only significant source of cash for the agency currently is the $3 billion in bonds approved by voters in 2004. Nearly half of that is committed. The latest financial report from CIRM shows its funding of research peaking in 2017-18.

During the last year or so, former CIRM Chairman Robert Klein has repeatedly discussed another bond measure and has even more recently expressed his desire to raise funds for a new electoral campaign. Klein resigned from his post last June. The CIRM board elected Jonathan Thomas, a Los Angeles bond financier, to replace Klein, who was the agency's first chairman and who led the 2004 ballot campaign.

In 2010, the CIRM board approved spending $700,000 for an Institute of Medicine study of CIRM with the expectation that its findings would enhance the likelihood of approval of more bond funding.

The IOM study is currently underway. The blue-ribbon panel is scheduled to hold a two-day public meeting in San Francisco Jan. 24-25 as part of its assessment of CIRM performance.

CIRM largely functions below the news media's radar, but talk of a new pitch for money has triggered negative commentary. Last month, the San Jose Mercury News said in an editorial that the agency should close its doors when its cash runs out because another bond measure would siphon off much-needed money for education and other critical services already "starved" by state budget cuts.

Backing away from another bond measure could benefit CIRM by helping to remove the likelihood that its actions will be judged in the context of an electoral campaign. But the action also raises the possibility that some of CIRM's best employees may leave for better prospects given that they may not have much of a future at an agency that would appear to be going out of business – at least at its current robust level.

The CIRM document dealing with the bond measure is dubbed a "transition plan" and is required by state law.

Instead of seeking to borrow more billions, the document said,

"CIRM should focus its efforts on creating a platform that enables others to carry on CIRM’s work. Through its funding of state of the art research facilities, collaborative funding agreements, and industry engagement, CIRM has already made progress in creating this platform."

The document also raised the possibility of creation of a nonprofit organization to carry on CIRM's stem cell research, a proposal that has floated quietly for some years. Such an effort could involve raising funds from the biotech industry, which CIRM is currently trying to engage in a more friendly way.

At the top of CIRM's list of transition plan activities is creation -- both nationally and internationally -- of "Alpha Stem Cell Clinics" for delivery of therapies to patients. The clinics also would foster clinical trials and evaluate cell therapies. Additionally included are efforts to drive "follow-on funding" for CIRM projects and strengthened efforts to support industry.

Directors could alter the CIRM transition plan at their meeting tomorrow. But it was placed on the agenda by Chairman Thomas and is unlikely to see major revisions.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Read More...

Adult Stem Cell Treatments for COPD -Real patient results, USA Stem Cells- Leon B. Testimonial – Video

January 20th, 2012 3:43 am

12-01-2012 07:24 If you would like more information please call us Toll Free at 877-578-7908. Or visit our website at http://www.usastemcells.com Or click here to have a Free Phone Constultation with Dr. Matthew Burks usastemcells.com Real patient testimonials for USA Stem Cells

The rest is here:
Adult Stem Cell Treatments for COPD -Real patient results, USA Stem Cells- Leon B. Testimonial - Video

Read More...

AFA opposed stem cells experiment on the Deaf babies – Video

January 20th, 2012 3:43 am

17-01-2012 00:52 AFA Denounces FDAs Approval of Newborn Stem Cell Experimentation Audism Free America (AFA), a grassroots Deaf activist network, condemns the United States Food and Drug Administration (FDA) for its approval of a study which will use cord blood stem cells on infants as young as six weeks old in an effort to eradicate the Deaf population of the United States. http://www.prweb.com audismfreeamerica.blogspot.com

Read more from the original source:
AFA opposed stem cells experiment on the Deaf babies - Video

Read More...

Suzanne Somers’ Stem Cell Breast Reconstruction Surgery – Episode 1 – Video

January 19th, 2012 10:33 am

30-12-2011 10:52 Watch Suzanne Somers' amazing breast reconstruction surgery on Suzanne Somers Breaking Through - Episode 1. See how Suzanne used her stem cells to regrow her breast after battling breast cancer. See a new episode of Suzanne Somers Breaking Through every Thursday! SUBSCRIBE NOW: http://www.youtube.com

Read more:
Suzanne Somers' Stem Cell Breast Reconstruction Surgery - Episode 1 - Video

Read More...

Breakthrough Fibromyalgia Treatment – Stem Cell Of America – Video

January 19th, 2012 10:33 am

15-01-2012 01:47 Fibromyalgia patients gets her life back.

Read the original here:
Breakthrough Fibromyalgia Treatment - Stem Cell Of America - Video

Read More...

Breakthrough Multiple Sclerosis Treatment – Stem Cell Of America – Video

January 19th, 2012 10:33 am

15-01-2012 02:10 Multiple Sclerosis patient is able to walk up and down stairs without a cane after treatment. - http://www.stemcellofamerica.com

Read this article:
Breakthrough Multiple Sclerosis Treatment - Stem Cell Of America - Video

Read More...

Selling hope with stem cells – Video

January 19th, 2012 6:35 am

16-01-2012 11:04 Stem cells hold the promise of one day solving our most puzzling medical problems. Those treatments are years away from being approved in Canada, but as a 16x9 investigation found, that hasn't stopped many clinics overseas from "Selling Hope" to desperate Canadians.

See original here:
Selling hope with stem cells - Video

Read More...

Cancer Immunotherapy – Virotherapy : Dr. Zihai Li – Stem Cells Which "Fool Immune System" – Video

January 18th, 2012 12:38 am

14-01-2012 07:17 NOTE: (Immunotherapy Research) Dr. Cassian Yee, Drs. Zihai Li and Bei Liu,, Zheng Cui, Ph.D, William Coley, Victor Ambros, Gary Ruvkun, and David Baulcombee youtu.be youtu.be youtu.be Research @ http://www.youtube.com youtu.be youtu.be UConn Health Center researchers have uncovered a way to potentially use human stem cells as a kind of vaccine against colon cancer.

See the rest here:
Cancer Immunotherapy - Virotherapy : Dr. Zihai Li - Stem Cells Which "Fool Immune System" - Video

Read More...

Banglore First Dental Stem Cell Bank is Now Open – Suvarna news – Video

January 18th, 2012 12:35 am

16-01-2012 01:56 SUVARNA NEWS 24X7 - http://www.suvarnanews.tv - 16 Jan 2011 - Banglore First Dental Stem Cell Bank is Now Open - Suvarna news

Read the rest here:
Banglore First Dental Stem Cell Bank is Now Open - Suvarna news - Video

Read More...

CBS 60 Minutes Stem Cells Scam Part 1 – Video

January 17th, 2012 12:46 am

10-01-2012 00:04 Charlatans offering Stem Cell Cures on Various Websites

Go here to see the original:
CBS 60 Minutes Stem Cells Scam Part 1 - Video

Read More...

Stem Cell #8 Vas Cath Removal 04/28/11 – Video

January 16th, 2012 4:30 pm

29-04-2011 10:25 After they harvested approx. 14 Million Stem Cells from the blood thru the catheter, they had to remove it....not a fun process. For more info on the Stem Cell Transplant Study for MS go to: http://www.MarcStemCell.com.

Excerpt from:
Stem Cell #8 Vas Cath Removal 04/28/11 - Video

Read More...

Ask the Doctors – Dental Stem Cell Banking – Video

January 16th, 2012 4:29 pm

11-01-2012 15:51 If you missed the opportunity to bank your child's cord blood, banking your child's baby or wisdom teeth is an option worth considering! StemSave offers recovery, transport and cryopreservation of the valuable stem cells found in teeth.An easy adjunct to the extraction of any healthy tooth, (examples include: wisdom teeth, baby teeth, tooth extractions related to orthodontia) StemSaving is easy and is available through your Dentist. For more information on banking teeth stem cells for your family's future health, visit http://www.stemsave.com or call 877-783-6728 (877-StemSave) today

Continue reading here:
Ask the Doctors - Dental Stem Cell Banking - Video

Read More...

Drug Reps Soften Their Sales Pitches, as pharma learns from Disney

January 15th, 2012 4:56 pm

Via Scoop.itinPharma

Drug makers are now asking their sales representatives to switch from making forceful, tightly scripted sales pitches to acting more like a resource supporting physicians’ treatment.
Via online.wsj.com

Source:
http://microarray.wordpress.com/feed/

Read More...

Drug Reps Soften Their Sales Pitches, as pharma learns from Disney

January 15th, 2012 4:54 pm

Via Scoop.itinPharma

Drug makers are now asking their sales representatives to switch from making forceful, tightly scripted sales pitches to acting more like a resource supporting physicians’ treatment.
Via online.wsj.com

Source:
http://microarray.wordpress.com/feed/

Read More...

Leading heart surgeon calls for ban on butter

January 15th, 2012 11:14 am

A British heart surgeon has issued a call for a ban on butter, citing excessive consumption of saturated fats which he believes has rapidly increased the number of heart disease cases in the Great Britain. Dr. Shyam Kolvekar expressed concern that people as young as 30 years old are now getting heart bypass surgery, an issue that he believes could be remedied by switching from butter to margarine or other "healthy" spreads.

Roughly 90 percent of British children eat too much saturated fat according to a U.K. diet survey. Eighty-eight percent of adult men and 83 percent of adult women also consume too much, averaging 20 percent over the recommended maximum. Some researchers believe that saturated fat contributes to high cholesterol and artery blockage. Read more...

Cardiofy Heart Care Supplement

Source:
http://feeds.feedburner.com/integratedmedicine

Read More...

HIV/AIDS: Advancing Stem Cell Therapies: 2011 CIRM Grantee Meeting – Video

January 15th, 2012 1:49 am

09-11-2011 13:11 Paula Cannon speaks at the 2011CIRM Grantee Meeting about a stem cell-based therapy for HIV/AIDS. Cannon is a co-principle investigator on a disease team that has the goal of engineering a person's own bone marrow to make the cells resistant to HIV

See the rest here:
HIV/AIDS: Advancing Stem Cell Therapies: 2011 CIRM Grantee Meeting - Video

Read More...

Why StemSave 2 – Video

January 14th, 2012 4:45 am

11-01-2012 11:36 StemSave offers recovery, transport and cryopreservation of the valuable stem cells found in teeth. An easy adjunct to the extraction of any healthy tooth, (examples include: wisdom teeth, baby teeth, tooth extractions related to orthodontia) StemSaving is easy and is available through your Dentist. For more information on banking teeth stem cells for your family's future health, visit http://www.stemsave.com or call 877-783-6728 (877-StemSave) today

Follow this link:
Why StemSave 2 - Video

Read More...

Page 1,527«..1020..1,5261,5271,5281,529..1,5401,550..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick